Investing Warburg Pincus Style

Warburg Pincus' favored health care business models eliminate as much time and risk as possible from the drug discovery and development process. Competition for such investments is increasing, but Warburg reckons its size, and experience, set it apart.

Warburg Pincus is one of the biggest private equity players, with more than $10 billion (€9.7 billion) of funds under management and a further $7 billion available to invest. The group has always had an interest in health care, and, over its 30-year history, has invested more than $3 billion in the sector ($600 million of which was invested in Europe).

Investment activity in health care has heated up over the past three years, explains Nick Lowcock, managing director of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.